Sienna Biopharmaceuticals, Inc.
SNNAQ · OTC
12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.06 | -0.02 | 0.00 |
| FCF Yield | -130.12% | -25.62% | -47.89% | -26.90% |
| EV / EBITDA | -0.38 | -1.79 | -1.37 | -2.93 |
| Quality | ||||
| ROIC | -92.02% | -37.55% | -40.65% | -234.14% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.81 | 0.84 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -49.26% | -130.79% | -78.01% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.24 | 1.54 | 0.44 | 0.45 |
| Interest Coverage | 0.00 | 0.00 | -36.42 | -20.31 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,490.96 | -7,169.21 | -9,212.16 | -9,193.44 |